Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (DE:38I)
FRANKFURT:38I
Holding DE:38I?
Track your performance easily
38I Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€11.14 - €31.78
Previous Close€11.92
Volume1.61K
Average Volume (3M)537.00
Market Cap
€1.18B
Enterprise Value€649.69M
Total Cash (Recent Filing)$658.11M
Total Debt (Recent Filing)$101.62M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Feb 20, 2025EPS Estimate
-€1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.45
Shares Outstanding101,848,572
10 Day Avg. Volume491
30 Day Avg. Volume537
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.26
Price to Sales (P/S)28.56
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.08
Enterprise Value/Gross Profit17.91
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
€49.72Price Target Upside317.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Intellia Therapeutics News
PremiumCompany Announcements
Intellia Therapeutics Announces Promising CRISPR Therapy Results
Bulls Say, Bears Say
Bulls Say
Efficacy Of NTLA-2002NTLA-2002 led to 92% reduction in HAE attacks in Ph1 and met all efficacy.
Long-term Effectiveness Of Nex-zNex-z one-time treatment resulted in a significant reduction of serum TTR, which was durable to 24 months, indicating long-term effectiveness.
Safety And Tolerability Of Nex-zNex-z continues to appear well-tolerated with treatment-related liver enzyme elevations seen in 6% of ATTR-CM patients being mild and transient.
Bears Say
Competitive LandscapeGrowing competition in the transthyretin amyloidosis (ATTR) space has pressured the stock.
Efficacy ConcernsIn recent trials, the 6-minute walk distance declined by approximately 19-24 meters in the treated group, showing no meaningful difference compared to placebo.
Market AcceptanceGene editing theoretically offers a one and done 'functional cure;' however, its irreversible nature makes the bar for market acceptance high, especially considering that the long-term safety implications are not known.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.74% Insiders
21.94% Mutual Funds
35.39% Other Institutional Investors
10.45% Public Companies and
Individual Investors
38I FAQ
What was Intellia Therapeutics’s price range in the past 12 months?
Intellia Therapeutics lowest stock price was €11.14 and its highest was €31.78 in the past 12 months.
What is Intellia Therapeutics’s market cap?
Currently, no data Available
When is Intellia Therapeutics’s upcoming earnings report date?
Intellia Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 61 days.
How were Intellia Therapeutics’s earnings last quarter?
Intellia Therapeutics released its earnings results on Nov 07, 2024. The company reported -€1.285 earnings per share for the quarter, beating the consensus estimate of -€1.333 by €0.048.
Is Intellia Therapeutics overvalued?
According to Wall Street analysts Intellia Therapeutics’s price is currently Undervalued.
Does Intellia Therapeutics pay dividends?
Intellia Therapeutics does not currently pay dividends.
What is Intellia Therapeutics’s EPS estimate?
Intellia Therapeutics’s EPS estimate is -€1.28.
How many shares outstanding does Intellia Therapeutics have?
Intellia Therapeutics has 101,848,570 shares outstanding.
What happened to Intellia Therapeutics’s price movement after its last earnings report?
Intellia Therapeutics reported an EPS of -€1.285 in its last earnings report, beating expectations of -€1.333. Following the earnings report the stock price went up 4.99%.
Which hedge fund is a major shareholder of Intellia Therapeutics?
Among the largest hedge funds holding Intellia Therapeutics’s share is ARK Investment Management LLC. It holds Intellia Therapeutics’s shares valued at 252M.
---
Intellia Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€49.72 (317.11% Upside)
€49.72 (317.11% Upside)
Blogger Sentiment
Bullish
DE:38I Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $38.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.87%
12-Months-Change
Fundamentals
Return on Equity
-52.23%
Trailing 12-Months
Asset Growth
-5.63%
Trailing 12-Months
Company Description
Intellia Therapeutics
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
---
38I Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented significant progress in Intellia's clinical pipeline and financial management, with notable achievements in CRISPR-based treatments and regulatory clearances. However, challenges such as decreased collaboration revenue and increased operational expenses were also highlighted.Read More>---
38I Revenue Breakdown
100.00% Collaboration revenue
---
38I Stock 12 Month Forecast
Average Price Target
€49.72
▲(317.11% Upside)
Technical Analysis
Intellia Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering 38I
1 Year
1 Year Success Rate
13/38 ratings generated profit
1 Year Average Return
+86.65%
reiterated a buy rating last month
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 34.21% of your transactions generating a profit, with an average return of +86.65% per trade.
---